Lantern Pharma Inc. (LTRN)
LTRN moved a median of 0.00% 30 minutes after news, and -0.88% by the close. How LTRN actually reacts to news — the realized, point-in-time move the market made, measured across 215 labeled events over the last three years with zero look-ahead.
LTRN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 213 |
| 30-min | 0.00% | 47% | 215 |
| 60-min | -0.24% | 45% | 215 |
| to close | -0.88% | 44% | 210 |
| Middle 50% of LTRN reactions | -2.20% to +2.05% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 215 |
Half of all Lantern Pharma Inc. news events land between -2.20% and +2.05% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when LTRN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LTRN's baseline. Nothing else.
Recent LTRN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form DEF 14A Lantern Pharma Inc. For: Oct 19 | SEC filing · Form DEF | SEC EDGAR | — | — | |
| Form PRE 14A Lantern Pharma Inc. For: Oct 08 | SEC filing · Form PRE | SEC EDGAR | -2.25% | -2.08% | |
| Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026 | Press release | Business Wire | +1.29% | -6.58% | |
| Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC | Press release | Business Wire | +2.22% | -4.59% | |
| Form 8-K Lantern Pharma Inc. For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -16.50% | |
| Form 8-K Lantern Pharma Inc. For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | +5.00% | +0.00% | |
| Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering | Press release | Business Wire | +5.00% | +0.00% | |
| Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering | Press release | Business Wire | -5.41% | -2.25% | |
| Form 8-K Lantern Pharma Inc. For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | -2.94% | -11.03% | |
| Form 8-K Lantern Pharma Inc. For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | +1.85% | +2.96% | |
| Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET | Press release | Business Wire | +1.85% | +2.96% | |
| Lantern Pharma Secures USPTO Notice of Allowance for LP-284 Treatment Patent in Aggressive B-Cell Lymphomas | Press release | Business Wire | -1.38% | -6.21% | |
| Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23 | Press release | Business Wire | +1.05% | -11.40% | |
| New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST) | Press release | ACCESS Newswire | +0.00% | -1.07% | |
| Form 10-Q Lantern Pharma Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.38% | +5.58% | |
| Form 8-K Lantern Pharma Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -4.38% | +5.58% | |
| Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | Business Wire | -4.38% | +5.58% | |
| Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET | Press release | Business Wire | +0.00% | -1.38% | |
| Form 8-K Lantern Pharma Inc. For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +3.66% | +0.73% | |
| Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine | Press release | Business Wire | -1.87% | -2.61% | |
| Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer | Press release | Business Wire | +0.00% | -6.81% | |
| Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers | Press release | Business Wire | -2.68% | +2.50% | |
| Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer | Press release | Business Wire | -1.15% | -11.18% | |
| Form EFFECT Lantern Pharma Inc. | SEC filing · Form EFFECT | SEC EDGAR | +2.60% | +1.04% | |
| Form S-1 Lantern Pharma Inc. | SEC filing · Form S-1 | SEC EDGAR | +2.76% | -7.29% | |
| Form 8-K Lantern Pharma Inc. For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | -2.86% | -2.86% | |
| Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer | Press release | Business Wire | -2.86% | -2.86% | |
| New to The Street Broadcasts Nationwide on Bloomberg Television Featuring "Opportunities To Consider(TM)" Across Artificial Intelligence, Healthcare Innovation, Fintech, Digital Assets, and Commodities | Press release | ACCESS Newswire | -1.14% | +6.25% | |
| Form D Lantern Pharma Inc. | SEC filing · Form D | SEC EDGAR | — | -2.06% | |
| Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC | Press release | Business Wire | -0.38% | +0.65% | |
| Form 10-Q Lantern Pharma Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.34% | +0.33% | |
| Form 8-K Lantern Pharma Inc. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -1.34% | +0.33% | |
| Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | Business Wire | -1.34% | +0.33% | |
| Form 8-K Lantern Pharma Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -10.60% | -4.56% | |
| Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor | Press release | Business Wire | -10.60% | -4.56% | |
| Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor | Press release | Business Wire | +7.32% | +22.44% | |
| Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026 | Press release | Business Wire | +2.19% | +0.49% | |
| Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™ | Press release | Business Wire | +1.87% | -4.67% | |
| Form 10-K/A Lantern Pharma Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.95% | -1.91% | |
| Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally | Press release | Business Wire | -2.63% | -13.16% | |
| CORRECTION: Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers | Press release | ACCESS Newswire | +7.39% | +6.96% | |
| Join Lantern Pharma on April 30 for the First Public Demonstration of with Zeta.ai - A Platform to Conquer Rare Cancers | Press release | ACCESS Newswire | +7.39% | +6.96% | |
| Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut | Press release | Business Wire | +7.39% | +6.96% | |
| Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity | Press release | Business Wire | +5.04% | +15.97% | |
| Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22 | Press release | Business Wire | -1.75% | +5.43% | |
| Form 8-K Lantern Pharma Inc. For: Apr 09 | SEC filing · Form 8-K | SEC EDGAR | +0.68% | +2.60% | |
| Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026 | Press release | Business Wire | -0.57% | +18.25% | |
| Form 10-K Lantern Pharma Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +3.53% | -2.84% | |
| Form 8-K Lantern Pharma Inc. For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +3.53% | -2.84% | |
| Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | Press release | Business Wire | +3.53% | -2.84% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LTRN section they belong to.
Where else LTRN is measured.
LTRN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Lantern Pharma Inc.'s median reaction calculated?
Every labeled LTRN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 215 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of LTRN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LTRN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.